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Aim: To assess whether spirometry done in hospital during an admission for an acute exacer-
bation of chronic obstructive pulmonary disease (AECOPD) is clinically useful for long-term 
management.
Methods: Patients admitted to hospital with a clinical diagnosis of AECOPD had spirometry 
post-bronchodilator at discharge and approximately 4 weeks later.
Results: Spirometry was achieved in less than half of those considered to have AECOPD. 
Of 49 patients who had spirometry on both occasions, 41 met the GOLD criteria for COPD at 
discharge and 39 of these met the criteria at 1 month. For the 41, spirometry was not statistically 
different between discharge and 1 month but often crossed arbitrary boundaries for classification 
of severity based on FEV1. The eight who did not meet GOLD criteria at discharge were either 
misclassified due to comorbidities that reduce FVC, or they did not have COPD as a cause of 
their hospital admission.
Conclusion: Spirometry done in hospital at the time of AECOP is useful in patients with a 
high pre-test probability of moderate-to-severe COPD. Small changes in spirometry at 1 month 
could place them up or down one grade of severity. Spirometry at discharge may be useful to 
detect those who warrant further investigation.
Keywords: classification of COPD, spirometry, acute exacerbation of COPD, primary care, 
cohort study
Introduction
The diagnosis of chronic obstructive pulmonary disease (COPD) is based on clinical 
features and spirometry.1 Spirometry is required in the assessment of severity which 
determines guideline treatment recommendations. It is also valuable to predict risk of 
death2 and readmission to hospital.3 In patients admitted to our hospital with an acute 
exacerbation of COPD (AECOPD), often spirometry appears to never have been done 
prior to admission, and is seldom done during admission. Primary care clinicians and 
patients need a confirmed diagnosis and severity classification to support manage-
ment decisions. There are often practical barriers to spirometry in the community,4 
whereas it may be readily accessible while patients are in hospital, with trained staff 
available to administer and interpret the test. However, Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines state that spirometry should be done 
“when the patient is clinically stable and free from respiratory tract infection”.1 The 
guideline injunction is based on concern that spirometry at this time might lead to false 
positive diagnosis or overestimation of severity. We wanted to explore the validity 
of this concern.
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There are only limited data available on the reproduc-
ibility of spirometry when comparing tests completed 
around the time of an AECOPD with tests done after reso-
lution of the acute episode.4–7 White and colleagues found 
that pre- and post-bronchodilator spirometry measurements 
were ‘stable’ between day 5 and day 28 on patients after 
initiating treatment for AECOPD.4 However, patients in 
this study were diagnosed and treated in primary care, and 
mostly had mild-to-moderate COPD – post bronchodilator 
Forced Expiratory Volume in 1 second (FEV1) was around 
60% of predicted. Similarly, Herpel and colleagues found 
relatively little change in spirometry in clinically stable 
patients with a wider range of COPD severity, but reported 
only pre-bronchodilator measurements.5 However, most 
patients in hospital with AECOPD are given frequent 
salbutamol or another short-acting bronchodilator, making 
valid pre-bronchodilator measurement difficult to achieve 
and raising concerns that to do so might interfere with 
therapy.
Donohue6 reported that the minimally clinical impor-
tant difference (MCID) in FEV1 is not definitively known, 
although major trials have used figures ranging from 45 to 
180 mL. Most studies use pre-bronchodilator tests, and a pre-
bronchodilator FEV1 improvement of about 100 mL corre-
lates with other important clinical outcomes. The author also 
noted that change in FEV1 can be practically useful only if it 
exceeds the bounds of measurement error, ie, mean change 
score for the group +/- 2SD; any smaller change would be 
indistinguishable from measurement error.
We therefore sought, in our patient population, to assess 
whether post-bronchodilation spirometry done in hospital just 
prior to discharge following a clinical diagnosis of AECOPD 
produces measurements which are not clinically different to 
measurements made 1 month later.
Methods
Participants
Patients were eligible if they were admitted to an adult 
medical ward at a large teaching hospital in New Zealand 
(  Middlemore Hospital) with a diagnosis of AECOPD. 
We note that there is no universally accepted definition of 
AECOPD but accept the criteria of the Canadian Thoracic 
Society which specifies a worsening of COPD symptoms 
leading to increased use of medications.7,8 Patients were 
excluded if they were discharged after-hours or over week-
ends or public holidays, or if they had a condition making 
technically adequate spirometry impossible, such as a stroke 
or dementia. Patients were recruited from September 2008 
to March 2009. The study was approved by the Northern X 
Regional Ethics Committee, ref NTX/07/11/123.
Spirometry
Spirometry was performed on a Microlab spirometer 
and Spida 5 software (both from Micro Medical Ltd, 
  Rochester, Kent, UK). These use NHANES III data for pre-
dicted values9 with a 10% correction factor for Polynesian 
people.10 We used ‘Caucasian’ values for European and 
‘Polynesian’ values for Maori and Pacific Island patients. 
The device was calibrated weekly. Testing was done by two 
registered nurses who were trained and certified to local stan-
dards which align with American Thoracic Society/European 
Respiratory Society standards.11 All spirometry was done 
post-bronchodilation. The protocol called for spirometry on 
the day of discharge and at home 30 days after discharge.
If a patient cannot produce a satisfactory Force Vital 
Capacity (FVC, defined as expiration for 6 seconds or   plateau 
on the volume-time curve), the FEV1/FVC ratio can be spu-
riously high due to an invalid FVC. This ratio may also be 
raised due to comorbidities limiting FVC. In this case the 
protocol called for the spirometry to be reviewed by a respi-
ratory physician (HR) looking for other features of COPD, 
in particular for a mid-expiratory concavity.
Analyses were based on detecting a statistically sig-
nificant change in FEV1 (see power calculations), a change 
sufficient to alter severity grading according to the GOLD 
criteria1 or a change that exceeded 100 mL or 150 mL (rep-
resenting the MCID).6
Power calculations
To determine whether spirometry was ‘stable’ over 1 month, 
we needed sufficient patients to allow us to detect the 
smallest clinically important change.
We assumed mean FEV1 at discharge as 1.5 L (SD 0.42); 
and that within-patient variation is 0.106 L (SD 0.10) (based 
on data from Herpel et al).5 The small standard deviation of 
the difference in repeated measures implies that the correlation 
between the measurements within-patient is relatively large. 
A series of power calculations were made. Using a correlation 
of 0.75, power of 90%, and a significance of 1%, we would need 
a sample size of 63 to detect a difference of 150 mL between 
two measures, or 36 to detect a difference of 200 mL.
Statistical analysis
We used Stata software for statistical analysis (v 10.1; 
  StataCorp, College Station, TX). Means are compared by 
paired t-test. Statistical significance is cited at P , 0.05.
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Results
Numbers at each stage of the recruitment process are given in 
Figure 1. Consent to join the study was given by 54, however 
four were excluded as unlikely to have COPD after review 
of all patient records by a respiratory physician (HR) who 
was blind to the study spirometry results. One had a history 
of childhood asthma and was a lifelong non-smoker. One 
had severe left sided heart failure, a 10 pack-year history of 
smoking, and normal spirometry in 2006. One had a 20 pack-
year history of smoking, stopping in 1975, normal spirometry 
in 2007, and a CT scan in 2009 that showed no evidence of 
COPD. One had normal spirometry in October 2009. One 
further patient declined the 1-month spirometry due to illness 
at the time, leaving data on 49 patients at both discharge and 
1 month. All 49 patients fitted the phenotype of COPD, with 
slowly progressive shortness of breath and cough and sputum 
production, onset in middle age, with a prolonged history of 
cigarette smoking, and having excluded asthma as the primary 
diagnosis. They all had a clinical diagnosis of COPD accepted 
by a senior clinician and met the criteria for AECOPD. The 
median number of admissions to hospital in the previous 
2 years, including the index admission, and for reasons that 
included COPD, was 3.5 with a range of 1 to 22.
Median time from admission to ‘discharge’ spirometry 
was 4 days (inter-quartile range 2 to 7). Median length of stay 
in hospital was 6 days (inter-quartile range 4 to 11). Counting 
from ‘discharge’ spirometry, data from the ‘1-month’ check 
was collected at a mean of 34.3 days (SD 6.3). Three patients 
were readmitted to hospital within 2 weeks of discharge, so 
we used their baseline spirometry collected at the end of the 
first admission, but counted days after discharge from their 
second discharge.
Forty-one patients met GOLD criteria for COPD at 
discharge and 39 of these met the criteria at 1 month. The 
two who no longer met GOLD criteria had FEV1/FVC of 
0.56 and 0.67 at discharge and 0.70 and 0.71 at 1 month, 
respectively (GOLD criteria specifies ,0.70). Their FEV1 
percentages predicted were 26 and 23 at discharge and 49 
and 45 at 1 month, respectively. Their FEV1 decreased from 
discharge to 1 month by 60 mL and 130 mL, respectively. 
One of the patients who did not meet GOLD criteria at dis-
charge did so at 1 month (FEV1/FVC 0.70 and 0.68, FEV1 
percent predicted 51 and 46, respectively).
For the 41 patients meeting GOLD criteria at discharge, 
mean patient age was 67.8 (SD 10.9) years, there were 
15 women, and the ethnic breakdown was 15 European, 
15 Maori, and 11 Pacific Island. Table 1 shows their spirom-
etry and severity classification at discharge and at 1 month. 
Spirometry change was not statistically significant. Apart 
from the two patients who no longer met GOLD COPD 
117 considered eligible 
66 invited, all consented
54 included 
49 completed spirometry at discharge and 1 month
41 met GOLD COPD criteria at discharge, 39 met the criteria at 1 month 
51 charge nurse or family deemed unfit to 
participate (mostly dementia, severe physical or
mental illness, infectious isolation) 
12 withdrew (3 died, 4 no longer cognitively 
capable, 1 family bereavement, 4 deteriorated
physical health) 
4 withdrawn as unlikely to have COPD (see text)
1 declined spirometry at 1 month 
Figure 1 Patient numbers in study.
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Table 1 Patients with COPD according to gOLD spirometry 
criteria at hospital discharge
Discharge 1 month P value
FEV1 1.04 (0.51) 1.08 (0.48) 0.26
FVC 2.09 (0.89) 2.18 (0.81) 0.12
FEV1/FVC 0.50 (0.11) 0.50 (0.12) 1.00
FEV1 % predicted 38.7 (14.4) 40.6 (14.3) 0.18
Classification (FEV1 % predicted)
Moderate (50 to ,80) 10
  Mild 0
  Moderate 8
  Severe 2
Severe (30 to ,50) 18
  Moderate 4
  Severe 11
  Very severe 2
Very severe (,30) 13
  Severe 6
  Very severe 6
Notes: Spirometry measures and GOLD severity classification at discharge and 
at 1 month. Results are mean (SD) or counts. N = 41. One ‘severe’ and one ‘very 
severe’ patient at discharge no longer met gOLD criteria at 1 month (see text).
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Figure 2 Difference between FEV1 at 1 month and FEV1 at discharge from hospital for each patient. Central line is observed average agreement. Upper and lower lines are 
95% limits of agreement.
Note: N = 41.
criteria, no patient moved more than one severity grade 
up or down. Following discharge, five patients decreased 
FEV1 by more than 200 mL, five patients decreased by more 
than 150 mL, and seven decreased by more than 100 mL; 
15 increased by more than 100 mL, 11 increased by more than 
150 mL, and nine increased by more than 200 mL. Individual 
changes for each of the 41 patients meeting GOLD criteria 
at discharge are shown in Figure 2. This figure shows that 
smaller or larger changes in FEV1 seem to occur regardless 
of mean value (which is an approximation of baseline or 
underlying value for each patient).
For the eight patients who failed to meet GOLD spirom-
etry criteria for COPD at discharge, mean age was 65.1 
(SD 8.7), five were women, and the ethnic breakdown was 
one European, five Maori, and two Pacific Islanders. At 
1 month they all had a FEV1/FVC ratio of 0.7 or greater.
Discussion
Between discharge and follow up at 1 month, post-
  bronchodilator spirometry did not significantly change 
and no patient moved more than one GOLD COPD sever-
ity grade up or down. Absolute changes were typically 
short of the MICD. These results were the same whether 
we considered all the patients who were clinically diag-
nosed as having AECOPD, those who met GOLD criteria 
for COPD at discharge, or those who met the criteria at 
1 month. We interpret these results to mean that spirometry 
done 4 days after admission is clinically stable over the 
following month.
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Of 41 patients who met GOLD COPD criteria at   discharge, 
only two did not meet the criteria at 1 month. In this group 
of patients it seems that false positive diagnosis from doing 
spirometry close to an acute exacerbation is not a clinical 
problem.
Although many patients crossed guideline classification 
boundaries of severity, with implications for guideline-based 
management decisions, we note that these boundaries are 
arbitrary points on a continuum. The GOLD guidelines state 
that they provide a “simple classification” “for educational 
reasons” using cut points “that have not been clinically 
validated”.1 Changes that shift patients across such boundar-
ies may reflect noise of measurement more than real airways 
change, which supports the need for clinical judgment when 
applying guidelines to individual patients.
Study strengths include testing patients from our own 
population, which has a unique ethnic mix. Limitations 
include a relatively small study size. Prior power calculations 
indicated that our 41 participants gave sufficient power to 
detect a change in FEV1 of 200 mL. The assumed standard 
deviation of samples proved correct. The assumed correlation 
0.75 between FEV1 at baseline and 1 month proved well short 
of the correlation 0.88 in our real sample (indicating greater 
‘stability’ or ‘lack of change’ than we had anticipated). 
Consistent with this was the mean change of 40 mL in our 
patients which was lower than the lowest MCID reported in 
the literature (45 mL) and well short of the more commonly 
used figures of 100 or 150 mL.6 For three patients, we used 
discharge spirometry from one admission, but repeat test-
ing was carried out 1 month after second admission shortly 
after the first. We would expect clinically that spirometry at 
the end of the first admission was either similar to, or worse 
than, spirometry at the end of the second admission – if the 
latter, then measurements for these patients would overes-
timate the change from discharge to 1 month. We note that 
less than half of those admitted with COPD were deemed fit 
for spirometry which may have introduced some selection 
bias into our study. We do not know whether those who did 
participate were more or less ‘stable’ in their spirometry than 
those who did not participate.
It is possible that our patients’ spirometry might have 
continued to improve past 1 month. However, Parker et al 
followed 20 patients for 60 days after an AECOPD and, 
while their patients took a mean of 41 days to symptomatic 
recovery, their FEV1 was back to baseline within about 
14 days.7 This implies that FEV1 is measuring a process that 
is associated with, rather than central to, the pathophysiol-
ogy of COPD. Indeed, Fabbri and Rabe suggest that COPD 
should no longer be considered a disease only of the lungs, 
but a chronic systemic inflammatory syndrome.12 A similar 
point was made by Celli et al who noted that the BODE index 
recognizes systemic manifestations not reflected in FEV1.2
Eight patients had been admitted to hospital with a clinical 
diagnosis of AECOPD, but failed to meet GOLD spirometry 
criteria at discharge, in each case due to FEV1/FVC being 
0.70 or greater. Percent predicted FEF25–75 (age adjusted) in 
these patients ranged from 12% to 73% and in each case the 
flow loop had a concave shape. Clinically it was considered 
that their FEV1/FVC may have been ‘artificially’ elevated 
due to a low FVC that was consistent in each case with 
known comorbidities, particularly obesity or congestive 
heart failure.
Our 41 patients with COPD at discharge had a mean 
of three comorbidities, including some with comorbidities 
that may decrease FVC (especially heart failure and obe-
sity) and therefore raise the FEV1/FVC ratio or may reduce 
airway caliber (especially obesity) and therefore decrease 
FEV1/FVC ratio. Others have commented on the high rate of 
false negative spirometry in patients who undoubtedly clini-
cally have COPD.13 There has also been criticism of the use 
of 0.7 as the cut point for FEV1/FVC ratio rather than using 
the lower limit of normal of an age predicted ratio;14,15 the 
problem of reduced lung volume with age was specifically 
noted in the GOLD guidelines.1 Our patients who did not 
meet COPD spirometry criteria at either time may have had 
mixed lung disease but should not be thereby denied COPD 
management. Such patients need more formal physiological 
assessment including lung volumes and diffusion capacity 
for carbon monoxide.
Guidelines state that spirometry should be performed 
when the patient is “stable and free from respiratory 
infection”.1 Apart from the fact that these patients are 
probably never free of respiratory infection, this restriction 
appears unnecessary, and in our own area this may be a bar-
rier to enrolment in the community chronic care management 
program. Our patients living in South Auckland often expe-
rience difficulties in accessing community services (due to 
cost, language barriers, travel, or taking time off work), and 
may therefore miss the opportunity for spirometry. Others 
have noted that it can be difficult to achieve spirometry in 
community general practice.4
The study suggests that, in patients with a high pre-test 
probability of COPD, spirometry at the time of discharge 
from hospital during an AECOPD can be used to confirm 
the diagnosis and to make an initial judgment about severity. 
However, for about one-fifth of our patients, the diagnosis of 
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COPD was cast in doubt by the spirometry results at 1 month, 
suggesting that they would warrant further investigation to 
confirm COPD or an alternative or additional diagnosis for 
their clinical symptoms. It would be helpful to have uni-
versally agreed criteria for grading severity – others have 
noted that some criteria may correlate better than others 
with outcomes.16
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